ÂÜÀòÂÒÂ×

Dr. Kalfus led the clinical and regulatory development of Talicia®, Redhill Biopharma’s treatment for Helicobacter pylori infection, which was FDA approved in 2019. Prior to that he was Chief Medical Officer at Thar Pharmaceuticals until its acquisition by Grunenthal in 2016. Dr. Kalfus was Vice President of Medical Affairs at Lev Pharmaceuticals, where he developed Cinryze®, the first HAE prophylaxis therapy, approved by FDA in 2008. Dr. Kalfus has extensive regulatory experience and has run national and international Phase 1-3 studies. His work has been published in the New England Journal of Medicine, Annals of Internal Medicine, American Journal of Emergency Medicine, American Journal of Gastroenterology, Annals of Allergy Asthma and Immunology, and JAMA among others.. Previous positions include Aetna/US Healthcare (Medical Director), Hillside Medical Associates (Internist), and Long Island Jewish Medical Center (President of the Staff Society and Chairman of Performance Improvement).

Dr. Kalfus completed residency and chief residency in Internal Medicine at Long Island Jewish Medical Center and graduated from Albert Einstein College of Medicine with an M.D. and Columbia University with a B.A. in Biology.